Navigation Links
Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
Date:7/29/2009

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, is scheduled to provide a corporate overview, including a discussion about the clinical development program for the Company's lead product candidate, picoplatin, at two upcoming investor conferences:

  • BMO Capital Markets 9th Annual Focus on Healthcare Conference
    • Wednesday, August 5, 2009 at 9:00 a.m. Eastern Time
    • Millennium Broadway Hotel in New York City
  • Canaccord Adams 29th Annual Global Growth Conference
    • Tuesday, August 11, 2009 at 1:30 p.m. Eastern Time
    • InterContinental Hotel in Boston

Live audio web casts of Poniard's presentations will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
11. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 2016 , ... For the 10,000 Americans who turn 65 on any given ... overall well-being: mental health. Now, a new book—Staying Sharp For Dummies (Paper; ISBN: 978-1-119-18779-0; ... which can include everything from honing your memory and managing stress to eating healthy ...
(Date:4/28/2016)... ... 2016 , ... Boston Laser is now offering a novel treatment for Keratoconus ... of the application of Riboflavin, a vitamin, to the cornea. This, combined with UV ... cornea to slow the progression of keratoconus. , Keratoconus is the continuous thinning and ...
(Date:4/28/2016)... ... April 28, 2016 , ... The USDA recently released its updated ... latest nutritional science. While there is a lot of information available in the report, ... the April 2016 issue of Harvard Men's Health Watch . , These ...
(Date:4/28/2016)... ... April 28, 2016 , ... Zerorez Franchising Systems, ... March 2-4. The conference featured several collaborative breakout sessions, presentations, an award banquet, ... franchisees felt they were given tools and resources to assist with operational growth ...
(Date:4/28/2016)... ... 2016 , ... It was the five star ratings and excellent reviews by ... Top Rated Atlanta Plastic Surgeon by Find Local Doctors. Dr. ... Specialists, P.C. This recognition is one of many achievements and awards that Dr. Jones ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... its digital health technology platform, which specializes in ... programs into scalable digital products, Zillion enables companies ... and empower consumers to take control of their ... live video conferencing – including one-to-one, group and ...
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
Breaking Medicine Technology: